PeerVoice Oncology & Haematology Audio

Nov 21 2024 114 ep. 29 mins 458
PeerVoice Oncology & Haematology Audio Podcast artwork

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  Science  Health & Fitness  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis

Nov 21 2024 20 mins  
Visit https://www.peervoice.com/TBB860 to view the entire programme with slides. After completing “John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis”, participants will be able to: Recognize the significant symptom- and treatment-related burdens associated with cytopeni

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Nov 15 2024 18 mins  
Visit https://www.peervoice.com/KAX860 to view the entire programme with slides. After completing “Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours”, participants will be able to: Discuss best practices in HER2 testing of solid tumours; and Interpret the clinical significance of HER2 scores on therapeutic management.

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Nov 15 2024 20 mins  
Visit https://www.peervoice.com/TUH860 to view the entire programme with slides. After completing “Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML”, participants will be able to: Recall clinical trial data evaluating first- and second-generation FLT3 inhibitors in the management of newly diagnosed F

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Nov 08 2024 57 mins  
Visit https://www.peervoice.com/JQU860 to view the entire programme with slides. After completing “Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice”, participants will be able to: Recognise the role of HER2 as a target in cancer sites beyond breast and gastric; Explain the HER2 testing and sc

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

Nov 08 2024 47 mins  
Visit https://www.peervoice.com/SYP860 to view the entire programme with slides. After completing “Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED”, participants will be able to: Evaluate current guidance for management of life-threatening bleeding in patients receiving direct oral antic

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Nov 08 2024 26 mins  
Visit https://www.peervoice.com/CJQ860 to view the entire programme with slides. After completing “Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts”, participants will be able to: Recall current guideline recommendations for the management of advanced colorectal cancer (CRC) beyond

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Nov 08 2024 59 mins  
Visit https://www.peervoice.com/NXK860 to view the entire programme with slides. After completing “Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals”, participants will be able to: Explain the current evidence-basis and recommendations for the use, timing, and sequencing of radiopharmaceuticals wi

Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Oct 25 2024 79 mins  
Visit https://www.peervoice.com/QFE860 to view the entire programme with slides. After completing “Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences”, participants will be able to: Evaluate clinical trial and real-world data which informs current evidence-based decision-making and treatment intensification

Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

Oct 25 2024 19 mins  
Visit https://www.peervoice.com/VCG860 to view the entire programme with slides. After completing “Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates”, participants will be able to: Describe patient-specific risk factors for the development of antibody-drug conjugate (ADC)-associated nausea/vomiting; and Propose

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Oct 11 2024 76 mins  
Visit https://www.peervoice.com/QWV860 to view the entire programme with slides. After completing “Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer”, participants will be able to: Describe antibody-drug conjugates (ADC)-based combination strategies that are in clinical development for HER2-positi